AWH(Delisted)
Aspira·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 4
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Three Black Crows
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AWH
Aspira Women’S Health Inc.
A bio-analytical based women’s health company that focused on gynecologic disease
12117 Bee Caves Road, Building III, Suite 100, Austin, Texas
--
Aspira Women's Health Inc., was originally incorporated in California on December 9, 1993 under the name of Nonbiological Systems, Inc. In March 1995, the company changed its name to Ciphergen Biosystems Holdings, Inc., and in May 2000, the company was reincorporated in Delaware. In September 2000, the company had its initial public offering. On November 13, 2006, the company sold its protein research tool assets, liabilities and collaboration services business (instrument business sale) to Bio-Rad Laboratories Ltd (Bio-Rad) to focus its resources on developing diagnostic products and services for clinical protein biomarkers. On August 21, 2007, the company changed its name to Vermillion Ltd.
Company Financials
EPS
AWH has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.21, beating expectations. The chart below visualizes how AWH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AWH has released its 2024 Q4 earnings report, with revenue of 2.35M, reflecting a YoY change of 10.28%, and net profit of -1.39M, showing a YoY change of 55.07%. The Sankey diagram below clearly presents AWH's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
